StockWatch
·

AMBALAL SARABHAI ENTERPRISES LTD. Q2 FY27 Results

AMBALALSAQ2 FY27 Results
Filing
Result:Steady· Market: Down#Turnaround#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue58.1333.5%30.8%
Total Income59.5230.6%29.2%
Expenditure58.1640.7%26.6%
PBT1.3667.9%1097.3%
Net Profit0.6783.0%220.4%
OPM4.13%6.30pp2.98pp
NPM1.13%7.59pp2.35pp
EPS0.0982.7%28.6%
View full financials

Revenue grew 30.8% YoY and PAT turned from a loss to a thin ₹0.67 Cr profit, but segment EBIT and NPM compressed sharply QoQ (margin to 1.1% from 8.7%) even as revenue rose, making this an ordinary, low-magnitude turnaround rather than a sector standout.

Q2 FY-2027 RESULTS · AMBALALSA

ASE swings to ₹0.67 Cr consolidated profit in Q2 FY27 as revenue grows 31% YoY

revenue +30.78% · margins expanding

05 Nov 2026 · 3 min read
Revenue

₹58.13 Cr

+30.78% YoY

PAT (consolidated)

₹0.67 Cr

Net margin

1.13%

+2.3pp YoY

EPS

₹0.09

Ambalal Sarabhai Enterprises reported consolidated revenue of ₹58.13 Cr for Q2 FY27 (quarter ended 30 Sep 2026), up 30.8% YoY from ₹44.45 Cr and up 33.4% QoQ from ₹43.56 Cr. Consolidated PAT turned around to a profit of ₹0.67 Cr against a loss of ₹0.56 Cr in the year-ago quarter — the YoY story is a turnaround, not a growth multiple, since the base was negative. Sequentially, however, PAT fell 83% from ₹3.98 Cr in Q1 FY27, and NPM compressed to roughly 1.1% from 8.7% in Q1 FY27 even as revenue rose, so the YoY turnaround should not be read as momentum — Q1's profitability was not sustained into Q2.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹58.13 Cr+33.4%+30.8%
Expenses₹58.16 Cr+40.7%+26.5%
PAT₹0.67 Cr-83.03%—
Net margin1.13%-7.6pp+2.3pp
EPS₹0.09-82.7%+28.6%

The margin squeeze sits on the operating line: combined segment EBIT fell to ₹2.36 Cr (Pharmaceuticals ₹1.08 Cr on ₹34.89 Cr revenue, Electronics ₹1.28 Cr on ₹23.28 Cr revenue) from ₹5.66 Cr in Q1 FY27, even though revenue was higher this quarter. Purchase of stock-in-trade (₹29.91 Cr) and employee costs (₹8.71 Cr) rose roughly in step with the topline, leaving less drop-through to EBIT; finance costs (₹1.04 Cr) and depreciation (₹1.39 Cr) were broadly stable QoQ. No exceptional items were booked in either the current or year-ago quarter, so the swing from a Q2 FY26 loss to a Q2 FY27 profit is entirely operating-driven, not one-off-driven.

₹
32.8537.1441.4345.71503608-0308-2509-1710-1211-0411-05Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹36, down 7.7% over the past month of trading.

₹ Cr
-1.612.025.659.288.22Q1 FY26rev ₹40 Cr-0.56Q2 FY26rev ₹44 Cr3.64Q3 FY26rev ₹52 Cr6.5Q4 FY26rev ₹65 Cr3.98Q1 FY27rev ₹44 Cr0.67Q2 FY27rev ₹58 Cr
Quarterly consolidated PAT, ₹ Crore

There is no formal management guidance on record for this company (none in our database, none found via web search), and no brokerage/consensus estimates for this micro-cap turned up in search either — so both vsGuidance and vsStreet are unknown rather than beat/miss. No management press release or commentary accompanies this filing beyond the routine board-outcome letter to BSE. The quarter's other disclosed developments — the trading-window closure from 25 Sep 2026 ahead of results, and the plant visit rescheduled to 1 Dec 2026 — are procedural and do not tie directly to this quarter's numbers. Q1 FY27 had been flagged in our records as "Income Up, PBT Surges"; this quarter's sharp QoQ PBT decline (₹1.32 Cr vs ₹4.68 Cr) shows that surge did not carry forward.

  • W1

    Whether consolidated segment EBIT recovers toward Q1 FY27's ₹5.66 Cr level or the sequential slide continues into Q3 FY27

  • W2

    Standalone parent's recurring losses (₹0.03 Cr this quarter) and whether its other-equity deficit (₹(17.15) Cr as of 30 Sep 2026) narrows

  • W3

    Any disclosures following the plant visit rescheduled to 1 Dec 2026

Informational and educational content only. Not investment advice.